TcdA and TcdB could induce the release of IL-1β by activating the inflammasome, which in turn triggers inflammation and intestinal damage, suggesting that the inhibition of the inflammasome or IL-1β signaling could be potential new strategies for treating CDI (Ng et al., 2010). The gene discussed is IL1B; the disease is clostridium difficile infection.